VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase II Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-in-Continuity (CIC)

VectivBio Holding AG announced positive interim data from the company’s ongoing Phase II STARS Nutrition study evaluating the safety, pharmacokinetics, and efficacy of apraglutide, an investigational new drug that is a next-generation, long-acting synthetic GLP-2 agonist, in adult patients with SBS-IF and CIC.